We are live on ! Find out more
CLGN icon

CollPlant Biotechnologies
CLGN

2 hedge funds and large institutions have $122K invested in CollPlant Biotechnologies in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
2
Holders Change
+2
Holders Change %
–
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$76.6K
2
UBS Group
UBS Group
Switzerland
+$54.2K

Top Sellers

No sellers this quarter

CLGN Hedge Fund Activity: Q3 2018 in Review

2 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q3 2018, worth a combined $122K.

Buyers outnumbered sellers: 2 funds opened new CLGN positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $76.6K.

  • 2 institutional investors held CollPlant Biotechnologies (CLGN) as of Q3 2018, up from 0 in Q2 2018.
  • Funds reported $122K of CollPlant Biotechnologies stock for Q3 2018.
  • 2 funds opened new CollPlant Biotechnologies positions in Q3 2018 and 0 closed out, a net change of +2 holders.
  • The largest CollPlant Biotechnologies buyer in Q3 2018 was Citadel Advisors, an estimated $76.6K added.

Based on aggregated 13F filings for Q3 2018.